Thermo Fisher Scientific Inc. $TMO Shares Acquired by Confluence Investment Management LLC

Confluence Investment Management LLC increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.9% during the 2nd quarter, Holdings Channel.com reports. The fund owned 92,781 shares of the medical research company’s stock after purchasing an additional 2,630 shares during the quarter. Confluence Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $46,517,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in TMO. Howard Capital Management Inc. increased its position in shares of Thermo Fisher Scientific by 0.5% during the fourth quarter. Howard Capital Management Inc. now owns 3,091 shares of the medical research company’s stock worth $1,791,000 after purchasing an additional 16 shares in the last quarter. Salomon & Ludwin LLC grew its stake in Thermo Fisher Scientific by 1.6% during the 4th quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company’s stock worth $669,000 after buying an additional 17 shares during the last quarter. Elwood & Goetz Wealth Advisory Group LLC increased its position in Thermo Fisher Scientific by 1.8% during the fourth quarter. Elwood & Goetz Wealth Advisory Group LLC now owns 1,031 shares of the medical research company’s stock worth $597,000 after buying an additional 18 shares during the period. Apella Capital LLC lifted its stake in Thermo Fisher Scientific by 2.5% in the fourth quarter. Apella Capital LLC now owns 744 shares of the medical research company’s stock valued at $431,000 after buying an additional 18 shares during the last quarter. Finally, Elyxium Wealth LLC boosted its holdings in shares of Thermo Fisher Scientific by 1.9% in the fourth quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company’s stock valued at $613,000 after acquiring an additional 20 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.0%

TMO stock opened at $574.29 on Tuesday. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $643.99. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The company has a fifty day moving average of $509.02 and a 200-day moving average of $511.04. The stock has a market capitalization of $213.42 billion, a PE ratio of 30.89, a price-to-earnings-growth ratio of 2.34 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same period in the prior year, the company posted $4.28 earnings per share. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the transaction, the chief operating officer owned 24,651 shares of the company’s stock, valued at $13,927,815. This represents a 1.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on TMO shares. Piper Sandler upped their price target on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a research report on Monday, July 27th. KeyCorp restated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Stifel Nicolaus dropped their price target on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research report on Friday, April 24th. Finally, Morgan Stanley increased their price objective on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $617.14.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.